Renadirsen, a Novel 2'OMeRNA/ENA


Journal

Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761

Informations de publication

Date de publication:
25 Sep 2021
Historique:
received: 02 08 2021
revised: 22 09 2021
accepted: 22 09 2021
entrez: 26 10 2021
pubmed: 27 10 2021
medline: 16 2 2022
Statut: epublish

Résumé

Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by out-of-frame or nonsense mutation in the dystrophin gene. It begins with a loss of ambulation between 9 and 14 years of age, followed by various other symptoms including cardiac dysfunction. Exon skipping of patients'

Identifiants

pubmed: 34698059
pii: cimb43030090
doi: 10.3390/cimb43030090
pmc: PMC8928966
doi:

Substances chimiques

Dystrophin 0
Oligodeoxyribonucleotides 0
Oligonucleotides, Antisense 0
Oligoribonucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1267-1281

Subventions

Organisme : Daiichi Sankyo Co., Ltd.
Organisme : Orphan Disease Treatment Institute Co., Ltd.

Références

J Biol Chem. 2008 Feb 29;283(9):5899-907
pubmed: 18083704
Nat Commun. 2017 Oct 16;8(1):941
pubmed: 29038471
Biochim Biophys Acta. 2010 Dec;1798(12):2296-303
pubmed: 20170628
Nat Med. 2015 Mar;21(3):270-5
pubmed: 25642938
Ann Neurol. 2016 Feb;79(2):257-71
pubmed: 26573217
ChemMedChem. 2007 Dec;2(12):1703-7
pubmed: 17910011
Expert Opin Biol Ther. 2013 Jun;13(6):875-88
pubmed: 23451977
Mol Ther. 2011 Mar;19(3):576-83
pubmed: 21179007
Nucleic Acid Ther. 2017 Jun;27(3):144-158
pubmed: 28375678
Adv Drug Deliv Rev. 2015 Jun 29;87:46-51
pubmed: 25666165
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203
pubmed: 15608067
Neuromuscul Disord. 2018 Jan;28(1):4-15
pubmed: 29203355
EMBO Rep. 2004 Sep;5(9):872-6
pubmed: 15470384
Mol Ther. 2008 May;16(5):832-5
pubmed: 18414480
Eur J Hum Genet. 2013 Oct;21(10):1049-53
pubmed: 23340516
Biol Pharm Bull. 2004 Apr;27(4):453-6
pubmed: 15056846
Nucleic Acids Res. 2002 May 1;30(9):1911-8
pubmed: 11972327
Nucleic Acids Res Suppl. 2001;(1):241-2
pubmed: 12836354
Nucleic Acids Res. 2014 Mar;42(5):3207-17
pubmed: 24366877
PLoS One. 2014 Nov 03;9(11):e111079
pubmed: 25365558
Kobe J Med Sci. 2015 Feb 17;60(4):E86-94
pubmed: 25791417
Mol Ther. 2010 Jun;18(6):1210-7
pubmed: 20407428
Bioorg Med Chem. 2003 May 15;11(10):2211-26
pubmed: 12713831
Nucleic Acids Res. 2003 Jun 15;31(12):3185-93
pubmed: 12799446
Sci Rep. 2015 Aug 20;5:12831
pubmed: 26290039
JAMA. 2016 Dec 13;316(22):2357-2358
pubmed: 27775756
Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):187-95
pubmed: 9212909
J Cardiovasc Pharmacol Ther. 2011 Mar;16(1):87-95
pubmed: 21304057
RNA Biol. 2010 Jul-Aug;7(4):453-61
pubmed: 20523110
Sci Rep. 2019 Apr 15;9(1):6078
pubmed: 30988454
Bioorg Med Chem Lett. 2002 Jan 7;12(1):73-6
pubmed: 11738576
Curr Opin Pharmacol. 2005 Oct;5(5):550-5
pubmed: 16087398
Lab Invest. 1997 Oct;77(4):379-88
pubmed: 9354772
Curr Opin Mol Ther. 2006 Apr;8(2):144-9
pubmed: 16610767
Genes (Basel). 2017 Feb 10;8(2):
pubmed: 28208626
Nat Genet. 1993 Apr;3(4):283-91
pubmed: 7981747
J Clin Invest. 1995 Feb;95(2):515-20
pubmed: 7860733
Lancet Neurol. 2014 Oct;13(10):987-96
pubmed: 25209738
Nat Biotechnol. 2017 Mar;35(3):230-237
pubmed: 28244996
Neuromuscul Disord. 1996 Oct;6(5):367-76
pubmed: 8938701
Am J Hum Genet. 2002 Aug;71(2):365-74
pubmed: 12111668
Hum Mol Genet. 2003 Apr 15;12(8):907-14
pubmed: 12668614
Science. 1989 Jun 30;244(4912):1578-80
pubmed: 2662404

Auteurs

Kentaro Ito (K)

Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Hideo Takakusa (H)

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Masayo Kakuta (M)

Medical Information Department, Daiichi Sankyo Co., Ltd., Chuo, Tokyo 1038426, Japan.

Akira Kanda (A)

Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Nana Takagi (N)

Safety and Risk Management Department, Daiichi Sankyo Co., Ltd., Chuo, Tokyo 1038426, Japan.

Hiroyuki Nagase (H)

Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Nobuaki Watanabe (N)

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Daigo Asano (D)

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Ryoya Goda (R)

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Takeshi Masuda (T)

Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1409710, Japan.

Akifumi Nakamura (A)

Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1409710, Japan.

Yoshiyuki Onishi (Y)

Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1409710, Japan.

Toshio Onoda (T)

Intellectual Property Department, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1409710, Japan.

Makoto Koizumi (M)

Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1409710, Japan.

Yasuhiro Takeshima (Y)

Department of Pediatrics, Hyogo College of Medicine, Nishinomiya 6638501, Japan.

Masafumi Matsuo (M)

Research Center for Locomotion Biology, Kobe Gakuin University, Nishi, Kobe 6512180, Japan.

Kiyosumi Takaishi (K)

Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 1408710, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH